BioStem Technologies, Inc. (OTCMKTS:BSEM) Short Interest Update

BioStem Technologies, Inc. (OTCMKTS:BSEM - Get Free Report) saw a large decrease in short interest during the month of May. As of May 15th, there was short interest totalling 74,600 shares, a decrease of 31.8% from the April 30th total of 109,400 shares. Currently, 0.4% of the company's stock are short sold. Based on an average daily volume of 157,200 shares, the short-interest ratio is presently 0.5 days.

BioStem Technologies Stock Performance

Shares of BSEM traded up $1.75 during trading hours on Tuesday, hitting $12.45. 142,602 shares of the company were exchanged, compared to its average volume of 67,283. The company has a market cap of $207.96 million, a PE ratio of 18.31 and a beta of -0.10. The firm's 50 day moving average is $11.59 and its 200-day moving average is $13.17. BioStem Technologies has a 52 week low of $6.77 and a 52 week high of $28.26.

BioStem Technologies (OTCMKTS:BSEM - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported $0.17 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.25 by ($1.08). The business had revenue of $72.53 million for the quarter, compared to the consensus estimate of $101.20 million. As a group, equities analysts forecast that BioStem Technologies will post 1.41 earnings per share for the current fiscal year.

BioStem Technologies Company Profile

BioStem Technologies, Inc, a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases.